Semaglutide and cancer: A systematic review and meta-analysis
Top Cited Papers
- 27 July 2023
- journal article
- review article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 17 (9) , 102834
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trialDiabetes, Obesity and Metabolism, 2018
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialDiabetes Care, 2017
- Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetesDiabetes, Obesity and Metabolism, 2017
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trialThe Lancet Diabetes & Endocrinology, 2017
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trialsDiabetes, Obesity and Metabolism, 2017
- A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid CancerExperimental Diabetes Research, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008